Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice

European Journal of Pharmacology

Volumn 571, Issue 1, 2007, Pages 51-54

  Adamek, Anna ^b   Jung, Susanne ^b   Dienesch, Charlotte ^b   Laser, Martin ^b   Ertl, Georg ^b   Bauersachs, Johann ^b   Frantz, Stefan ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE

Author keywords

5 Lipoxygenase; Inflammation; Ischemia reperfusion; Leukotriene

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; LEUKOTRIENE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; IN VIVO STUDY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; RISK ASSESSMENT; STATISTICAL ANALYSIS; WILD TYPE;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LEUKOTRIENES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEUTROPHIL INFILTRATION; RISK FACTORS; RNA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548051403     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.040     Document Type: Article

References (24)

1. Bednar M., Smith B., Pinto A., and Mullane K.M. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ. Res. 57 (1985) 131-141
2. Carry M., Korley V., Willerson J.T., Weigelt L., Ford-Hutchinson A.W., and Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 85 (1992) 230-236
3. Chatterjee P.K., Patel N.S., Cuzzocrea S., Brown P.A., Stewart K.N., Mota-Filipe H., Britti D., Eberhardt W., Pfeilschifter J., and Thiemermann C. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc. Res. 61 (2004) 630-643
4. Chen X.S., Sheller J.R., Johnson E.N., and Funk C.D. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372 (1994) 179-182
5. Cuzzocrea S., Rossi A., Serraino I., Di Paola R., Dugo L., Genovese T., Caputi A.P., and Sautebin L. 5-lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock. Shock 20 (2003) 230-236
6. Fiedler V.B., and Mardin M. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog. J. Cardiovasc. Pharmacol. 7 (1985) 983-989
7. Ford-Hutchinson A.W. Leukotriene B4 in inflammation. Crit. Rev. Immunol. 10 (1990) 1-12
8. Frangogiannis N.G., Smith C.W., and Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 53 (2002) 31-47
9. Frantz S., Hu K., Widder J., Bayer B., Witzel C.C., Schmidt I., Galuppo P., Strotmann J., Ertl G., and Bauersachs J. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br. J. Pharmacol. 141 (2004) 9-14
10. Frantz S., Calvillo L., Tillmanns J., Elbing I., Dienesch C., Bischoff H., Ertl G., and Bauersachs J. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J. 19 (2005) 591-593
11. Goulet J.L., Snouwaert J.N., Latour A.M., Coffman T.M., and Koller B.H. Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci. 91 (1994) 12852-12856
12. Gross G.J., Falck J.R., Gross E.R., Isbell M., Moore J., and Nithipatikom K. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc. Res. 68 (2005) 18-25
13. Hahn R.A., MacDonald B.R., Simpson P.J., Potts B.D., and Parli C.J. Antagonism of leukotriene B4 receptors does not limit canine myocardial infarct size. J. Pharmacol. Exp. Ther. 253 (1990) 58-66
14. Helgadottir A., Manolescu A., Helgason A., Thorleifsson G., Thorsteinsdottir U., Gudbjartsson D.F., Gretarsdottir S., Magnusson K.P., Gudmundsson G., Hicks A., Jonsson T., Grant S.F., Sainz J., O'Brien S.J., Sveinbjornsdottir S., Valdimarsson E.M., Matthiasson S.E., Levey A.I., Abramson J.L., Reilly M.P., Vaccarino V., Wolfe M.L., Gudnason V., Quyyumi A.A., Topol E.J., Rader D.J., Thorgeirsson G., Gulcher J.R., Hakonarson H., Kong A., and Stefansson K. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 38 (2006) 68-74
15. Kitagawa K., Matsumoto M., and Hori M. Cerebral ischemia in 5-lipoxygenase knockout mice. Brain Res. 1004 (2004) 198-202
16. Maxwell M.P., Marston C., Hadley M.R., Salmon J.A., and Garland L.G. Selective 5-lipoxygenase inhibitor BW A4C does not influence progression of tissue injury in a canine model of regional myocardial ischaemia and reperfusion. J. Cardiovasc. Pharmacol. 17 (1991) 539-545
17. Mullane K., Hatala M.A., Kraemer R., Sessa W., and Westlin W. Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes. J. Cardiovasc. Pharmacol. 10 (1987) 398-406
18. Romson J.L., Hook B.G., Kunkel S.L., Abrams G.D., Schork M.A., and Lucchesi B.R. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67 (1983) 1016-1023
19. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
20. Sasaki K., Ueno A., Katori M., and Kikawada R. Detection of leukotriene B4 in cardiac tissue and its role in infarct extension through leucocyte migration. Cardiovasc. Res. 22 (1988) 142-148
21. Seubert J.M., Zeldin D.C., Nithipatikom K., and Gross G.J. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 82 (2007) 50-59
22. Shekher A., and Singh M. Role of eicosanoid inhibition of ischemia reperfusion injury: intact and isolated rat heart studies. Methods Find. Exp. Clin. Pharmacol. 19 (1997) 223-229
23. Vanags D., Williams B., Johnson B., Hall S., Nash P., Taylor A., Weiss J., and Feeney D. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 368 (2006) 855-863
24. Welt K., Fitzl G., and Mark B. Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury? An ultrastructural-morphometric study. Exp. Toxicol. Pathol. 52 (2000) 27-36